{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:53:59Z","timestamp":1791179639890,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have substantially improved long-term oncologic outcomes in patients with advanced malignancies; however, ICI-related cardiovascular adverse events have emerged as a growing clinical challenge. Accumulating clinical evidence confirms that ICI treatment markedly increases the risk of atherosclerotic cardiovascular disease (ASCVD). Although cardiovascular toxicities secondary to ICIs are relatively infrequent, these complications carry severe and potentially fatal clinical consequences. Herein, we describe a rare case of acute non-ST-segment elevation myocardial infarction (NSTEMI) complicated by accelerated atherosclerosis potentially associated with ICI therapy in a middle-aged woman with advanced cervical squamous cell carcinoma harboring proficient mismatch repair (pMMR) status. Following successful coronary revascularization, the patient safely reinitiated immunotherapy and achieved long-term sustained tumor-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 39-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical squamous cell carcinoma, with comorbid type 2 diabetes mellitus and hypertension. She received first-line quadruple combination therapy comprising nab-paclitaxel, cisplatin, bevacizumab, and tislelizumab. Complete tumor response was achieved following six cycles of systemic treatment. Subsequent maintenance therapy combined with pelvic radiotherapy enabled sustained disease remission for more than 5 years. Approximately 2 years after transitioning to single-agent tislelizumab maintenance, the patient experienced an acute NSTEMI. Coronary angiography demonstrated severe multivessel coronary stenosis, and percutaneous coronary intervention (PCI) was performed successfully. After thorough multidisciplinary cardio-oncology evaluation, tislelizumab was safely reinitiated and continued until August 2024. At the most recent follow-up in June 2026, the patient maintained a persistent complete response with stable cardiac function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that patients with advanced pMMR cervical cancer complicated by diabetes and hypertension can achieve durable complete remission exceeding 5 years with tislelizumab-based combination regimens. Furthermore, this case report also suggests that ICIs may be associated with cardiovascular events secondary to accelerated atherosclerosis, and demonstrates the clinical feasibility of safely resuming immune-checkpoint-inhibitor therapy following myocardial infarction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1947402","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:31:43Z","timestamp":1791178303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Qingyun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Weifang People\u2019s Hospital (The First Affiliated Hospital of Shandong Second Medical University)","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Sunshine Union Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sunshine Union Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang People\u2019s Hospital (The First Affiliated Hospital of Shandong Second Medical University)","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingning","family":"Fu","sequence":"additional","affiliation":[{"name":"Center for Precision Pathological Diagnosis, Weifang People\u2019s Hospital (The First Affiliated Hospital of Shandong Second Medical University)","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang People\u2019s Hospital (The First Affiliated Hospital of Shandong Second Medical University)","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Weifang People\u2019s Hospital (The First Affiliated Hospital of Shandong Second Medical University)","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","volume-title":"Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Cervical Cancer 2025[M]","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3322\/caac.21560","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12916-024-03261-x","article-title":"Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium","volume":"22","author":"Gong","year":"2024","journal-title":"BMC Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the New-An evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cancergen.2025.06.002","article-title":"Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer","author":"Higa","year":"2025","journal-title":"Cancer Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/imr.13301","article-title":"Decoding immunogenic cell death from a dendritic cell perspective","volume":"321","author":"Janssens","year":"2024","journal-title":"Immunol. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"26","author":"Kabir","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1573202","DOI":"10.3389\/fimmu.2025.1573202","article-title":"Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report","volume":"16","author":"Lang","year":"2025","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: clinical presentation and molecular understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cancergen.2025.05.006","article-title":"Acute cardiac dysfunction in patients with ovarian cancer treated with niraparib due to TFAM mutation: a case series and functional analysis","author":"Liu","year":"2025","journal-title":"Cancer Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e207550","DOI":"10.1172\/JCI207550","article-title":"Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy","volume":"136","author":"Lu","year":"2026","journal-title":"J. Clin. Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e001901","DOI":"10.1136\/jitc-2020-001901","article-title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","volume":"9","author":"Marron","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaccao.2025.06.008","article-title":"Cancer-related immune therapies: bidirectional implications from cardiotoxicity to emerging cardiovascular therapeutics: JACC CardioOncology state-of-the-art review","volume":"7","author":"Miteva","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy Versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s44161-025-00713-2","article-title":"Progenitor exhausted PD-1(+) T cells are cellular targets of immune checkpoint inhibition in atherosclerosis","volume":"4","author":"Mulholland","year":"2025","journal-title":"Nat. Cardiovasc Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","article-title":"Identification of new immune target and signaling for cancer immunotherapy","author":"Narote","year":"2025","journal-title":"Cancer Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/cdt3.70017","article-title":"Tislelizumab: structural innovations and expanding clinical Horizons in next-generation PD-1 immunotherapy","volume":"11","author":"Nguyen","year":"2025","journal-title":"Chronic Dis. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2024.12.020","article-title":"Pembrolizumab in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) and non-MSI-H\/non-dMMR advanced endometrial cancer: phase 2 KEYNOTE-158 study results","volume":"193","author":"O'Malley","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer","volume":"385","author":"Palaskas","year":"2024","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","article-title":"Molecular mechanisms governing CD8 T cell differentiation and checkpoint inhibitor response in cancer","volume":"43","author":"Rausch","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1305810","DOI":"10.3389\/fimmu.2024.1305810","article-title":"Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40959-025-00406-6","article-title":"Real-world analysis of cardiovascular adverse events and risk factors after immune checkpoint inhibitor therapy","volume":"11","author":"Wang","year":"2025","journal-title":"Cardiooncology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103308","DOI":"10.1016\/j.eclinm.2025.103308","article-title":"A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer","volume":"85","author":"Wen","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/CCO.0000000000000663","article-title":"Advances in immunotherapy for cervical cancer","volume":"32","author":"Wendel","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101383","DOI":"10.1016\/j.tranon.2022.101383","article-title":"Cardiovascular toxicity following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"19","author":"Xavier","year":"2022","journal-title":"Transl. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ijgo.70280","article-title":"Immune checkpoint inhibitors in gynecologic oncology: current status and perspectives","volume":"171","author":"Yanaihara","year":"2025","journal-title":"Int. J. Gynecol. and Obstetrics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1947402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:31:44Z","timestamp":1791178304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1947402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":32,"alternative-id":["10.3389\/fphar.2026.1947402"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1947402","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1947402"}}